Mouse VEGFR3 / FLT-4 Protein (Fc Tag)
AI323512,Chy,Flt-4,VEGFR-3,VEGFR3
- 100ug (NPP1616) Please inquiry
| Catalog Number | P50584-M02H |
|---|---|
| Organism Species | Mouse |
| Host | Human Cells |
| Synonyms | AI323512,Chy,Flt-4,VEGFR-3,VEGFR3 |
| Molecular Weight | The secreted recombinant mouse FLT4/Fc chimera is a disulfide-linked homodimer. The reduced monomer consists of 992 amino acids and has a predicted molecular mass of 112 kDa. As a result of glycosylation and proteolytic cleavage, rm FLT4/Fc monomer migrates as three bands (150, 85, 65 kDa) corresponding to the full length and the cleaved two polypeptides respectively in SDS-PAGE under reducing conditions. |
| predicted N | Tyr 25 |
| SDS-PAGE |  |
| Purity | > 92 % as determined by SDS-PAGE |
| Protein Construction | A DNA sequence encoding the mouse FLT4 (P35917-1) extracellular domain (Met 1-Glu 775) was was fused with the Fc region of human IgG1 at the C-terminus. |
| Bio-activity | 1. Measured by its ability to bind human VEGF-D (P 10557-H08H) in functional ELISA. 2. Immobilized human VEGF-C (P 10542-H08H) at 10 μg/mL (100 μL/well) can bind mouse VEGFR3-Fc. The EC50 of mouse VEGFR3-Fc is 0.008 μg/mL. 3. Measured by its ability to bind with mouse FIGF-His (P50157-M08H) in a functional ELISA. |
| Research Area | Cancer |Signal transduction |Protein Kinase |Receptor Tyrosine Kinase (RTK) |
| Formulation | Lyophilized from sterile PBS, pH 7.4 1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. |
| Background | Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on. |
| Reference |